LitAlert ~~ GeneLit.com

    • Real-world study of patients with germline BRCA1/2-mutated human epidermal growth factor receptor 2-Negative advanced breast cancer: Patient demographics, treatment patterns, adverse events, and physician-reported satisfaction in the United States, Europe, and Israel.
    • Mahtani R, Niyazov A, Arondekar B, Lewis K, Rider A, Massey L, Lux MP.
    • Breast. 2022 Oct 18:S0960-9776(22)00174-6. doi: 10.1016/j.breast.2022.10.009. Epub ahead of print.

    • Therapeutic effect and safety of individualized chemotherapy combined with sequential immunotherapy based on BRCA1 mRNA expression level in the treatment of unresectable pancreatic cancer.
    • Du J, Zhu L, Sha H, Zou Z, Zhao L, Shen J, Kong W, Qiu Y, Liu B.
    • Front Oncol. 2022 Oct 18;12:1015232. doi: 10.3389/fonc.2022.1015232.

    • Clinical decisions by the molecular tumor board on comprehensive genomic profiling tests in Japan: A retrospective observational study.
    • Shirota H, Komine K, Takahashi M, Takahashi S, Miyauchi E, Niizuma H, Tada H, Shimada M, Niihori T, Aoki Y, Sugiyama I, Kawamura M, Yasuda J, Suzuki S, Iwaya T, Saito M, Saito T, Shibata H, Furukawa T, Ishioka C.
    • Cancer Med. 2022 Oct 17. doi: 10.1002/cam4.5349. Epub ahead of print.

    • The synthetic lethality of targeting cell cycle checkpoints and PARPs in cancer treatment.
    • Li S, Wang L, Wang Y, Zhang C, Hong Z, Han Z.
    • J Hematol Oncol. 2022 Oct 17;15(1):147. doi: 10.1186/s13045-022-01360-x.

    • A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes.
    • Gruber JJ, Afghahi A, Timms K, DeWees A, Gross W, Aushev VN, Wu HT, Balcioglu M, Sethi H, Scott D, Foran J, McMillan A, Ford JM, Telli ML.
    • Nat Cancer. 2022 Oct 17. doi: 10.1038/s43018-022-00439-1. Epub ahead of print.

    Related:

    Identifier: NCT02401347: Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors. (ClinicalTrials.gov . Accessed 2022 Oct 18.)

    Identifier: NCT04756765: Talazoparib Monotherapy in PALB2 Mutation Associated Advanced Breast Cancer. (ClinicalTrials.gov . Accessed 2022 Oct 18.)

    • Optimizing Therapy for Ovarian Cancer: Recent Data Highlights - Episode 3: PARP Inhibitors as Frontline Maintenance Therapy in Ovarian Cancer.
    • Monk BJ, Coleman RL, Westin SN, Birrer MJ.
    • OncLive. Peer Exchange. 2022 Oct 17.

    • Optimizing Therapy for Ovarian Cancer: Recent Data Highlights - Episode 4: Olaparib Combinations for Frontline Maintenance Therapy in Ovarian Cancer Treatment: The PAOLA-1 Trial.
    • Monk BJ, Coleman RL, Westin SN, Birrer MJ.
    • OncLive. Peer Exchange. 2022 Oct 17.